PHARMACYTE BIOTECH, INC. — Income Charts
2 years of history · ending 2025-04-30 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
$0
Cost of Revenue
—
Gross Profit
—
R&D
$438K
D&A
—
Operating Income
$-4M
EBITDA
$-4M
Interest Expense
—
Tax Provision
$0
Net Income
$31M
Gross Margin
—
Operating Margin
—
Net Margin
—
Deferred Tax Assets
$15M
DTA Valuation Allowance
$15M
NOL Carryforwards
$61M
ETR (Continuing Operations)
—
ETR Federal Statutory
—
Operating Lease Cost
$28K
Revenue YoY Variation
—
Income YoY Variation
48.6%